Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

481
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
481
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

466
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
466
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

806
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
806
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

409
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
409

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Significance of Model-Based Strategies in Drug Development throughout the Lifecycle and Regulatory Decision-Making.

Current reviews in clinical and experimental pharmacology·2026
Same author

Economic and environmental impact of reducing unnecessary coagulation screen testing on an acute medical unit: a quality improvement project.

Postgraduate medical journal·2026
Same author

Risk factors associated with acquiring gastrointestinal infections in UK international travellers: a case-control study.

Epidemiology and infection·2026
Same author

Is pre-travel advice followed? A study of UK international travellers with gastrointestinal illness and asymptomatic travellers.

Public health·2025
Same author

Parenting and COVID-19: qualitative study of educational challenges, childcare and crisis-related decision-making in diplomatic families.

BMC psychology·2025
Same author

Identifying, communicating, and de-escalating risk in high-stakes settings: How conversation analysis research can underpin communication training.

Patient education and counseling·2025

Related Experiment Video

Updated: Apr 23, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.1K

Warfarin-induced deep vein thrombosis.

Khalid A Binymin1, Magda Nasher2, Dipti Patel2

  • 1Liverpool University, Medical School, England, UK.

International Medical Case Reports Journal
|September 24, 2014
PubMed
Summary

A "slow-start regimen" for warfarin may paradoxically increase deep vein thrombosis (DVT) risk. This occurs due to initial warfarin doses causing a hypercoagulable state by reducing crucial anticoagulant proteins.

Keywords:
deep vein thrombosisprotein Cprotein Sslow-start regimenstroke prophylaxiswarfarinwarfarin-induced skin necrosis

More Related Videos

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography
06:44

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography

Published on: April 13, 2018

9.6K
Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis
05:37

Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis

Published on: December 22, 2017

25.7K

Related Experiment Videos

Last Updated: Apr 23, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.1K
Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography
06:44

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography

Published on: April 13, 2018

9.6K
Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis
05:37

Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis

Published on: December 22, 2017

25.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Hematology

Background:

  • Atrial fibrillation necessitates anticoagulation to prevent stroke.
  • Warfarin is a common oral anticoagulant used for stroke prophylaxis.
  • A
  • slow-start regimen
  • involves initiating warfarin without immediate heparin cover.

Observation:

  • A 72-year-old female with atrial fibrillation developed deep vein thrombosis (DVT) in her left leg.
  • She was on warfarin therapy initiated 3 days prior, following a
  • slow-start regimen
  • without low molecular weight heparin.
  • Her warfarin dose was increased after 3 days to accelerate anticoagulation.

Findings:

  • The patient's DVT occurred despite initiating warfarin therapy.
  • It is proposed that the higher, unopposed warfarin dose led to DVT.
  • Warfarin loading doses can paradoxically induce a hypercoagulable state.

Implications:

  • Elevated warfarin doses may increase thrombosis risk due to reduced protein C and S levels.
  • Clinical protocols for initiating warfarin may require re-evaluation.
  • Understanding warfarin's procoagulant effects during initial dosing is critical for patient safety.